<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The extent and importance of autoimmune mechanisms in <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and the role of immunosuppression in the treatment of this disease are not well defined </plain></SENT>
<SENT sid="1" pm="."><plain>We report overrepresentation of HLA-DR2 and its serologic split HLA-DR15 in both <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AA) </plain></SENT>
<SENT sid="2" pm="."><plain>Four clinically and ethnically defined patient groups were analyzed </plain></SENT>
<SENT sid="3" pm="."><plain>The HLA-DR15 antigen frequencies among North American white <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients (n = 72) and AA patients (n = 59), who received immunosuppressive treatment at the National Institutes of Health (NIH), were 36% and 42%, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>These antigen frequencies were significantly higher than that of the control population of 240 North American white NIH blood donors typed for HLA antigens by the same molecular technique (HLA-DR15, 21.3%, P =.01 for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, P &lt;.001 for AA) </plain></SENT>
<SENT sid="5" pm="."><plain>Among North American white patients reported in the International Bone Marrow Transplant Registry (IBMTR), 30% of 341 MDS patients and 33% of 364 AA patients were positive for HLA-DR2 </plain></SENT>
<SENT sid="6" pm="."><plain>These antigen frequencies were higher than those reported for the general North American white population (HLA-DR2, 25.3%, P =.089 for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, P =.01 for AA) </plain></SENT>
<SENT sid="7" pm="."><plain>The DR15 and DR2 frequencies were significantly increased in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA) (P =.036 and P =.01, respectively) but not <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts </plain></SENT>
<SENT sid="8" pm="."><plain>In the NIH <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients, HLA-DR15 was significantly associated with a clinically relevant response to antithymocyte globulin (ATG) or <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> immunosuppression (multivariate analysis, P =.008) </plain></SENT>
<SENT sid="9" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with RA, DR15 may be useful as a guide to pathophysiology, prognosis, and treatment </plain></SENT>
</text></document>